Vladimir Vorobyev

4PUBLICATIONS
40CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jun 06, 2023
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.

Talha Munir, Carol Moreno, Carolyn Owen

|Oct 26, 2022
[Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience].

V A Zherebtsova, V I Vorobyev, E G Gemdzhian

|Oct 26, 2022
[Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].

V I Vorobyev, E G Gemdzhian, L V Fedorova

|Dec 15, 2021
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.

Keith W Pratz, Brian A Jonas, Vinod Pullarkat

Pageof 1

Frequent Collaborators

2 joint publications

E G Gemdzhian

2 joint publications

V V Ptushkin

2 joint publications

V A Zherebtsova

1 joint publications

L V Fedorova